What is news?
The upcoming ex-4 mission for the International Space Station (ISS) can have a significant impact on the treatment of diabetes. The United Arab Emirates (UAE) healthcare provider Burjil Holdings is using an experiment on the behavior of glucose in microgravity situations. Indian astronaut Shubhanshu Shukla will be part of this unprecedented study during his 14-day stay at the Orbital Lab. Some astronauts will wear constant glucose monitors as part of the ‘suite ride’ experiment.
Objective
What is the purpose of experiment?
The goal of this experiment is to study how glucose and insulin behave in microgravity conditions. This research can be helpful in the development of wearable tools for patients unable to move due to conditions such as astronauts and paralysis. Continuous glucose monitor as well as astronauts will take insulin pens in refrigerated and ambient temperatures. Its purpose is to see how these molecules behave in microgravity conditions.
Astronauts suffering from diabetes will benefit
Mohammad Fitayana, Chief Medical Officer of Burjil Holdings, told PTI, “We are trying to see if there is any change or fluctuations in blood sugar levels while in space.” Currently NASA does not allow diabetics to travel to space. This study may change the future of space travel for astronauts suffering from diabetes dependent on insulin.
It will also be used to make new medicines
Research can also identify new medicinal goals by looking at how metabolic and hormonal reactions in microgravity change. This can potentially cause medicines that increase insulin sensitivity or mimic the benefits of exercise in sedentary individuals. Artificial Intelligence (AI)-Appearance model operated in space can be adapted to make the care of diabetes on earth individuals in space.
Follow Us On Google News
Follow Us On WhatsApp
Leave a Comment